The phase 3 PhALLCON trial showed a trend toward improved EFS in patients with Ph+ newly diagnosed ALL when treated with ponatinib compared with imatinib.
Lisocabtagene maraleucel is a CD19-directed genetically modified autologous T cell immunotherapy.
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
Zanubrutinib prolongs progression-free survival, when compared with ibrutinib, in patients with relapsed/refractory CLL/SLL, a phase 3 trial suggests.
Researchers sought to determine whether uMRD could determine discontinuation of venetoclax or the addition of ibrutinib in patients with R/R CLL.
Researchers sought to determine whether adding anti-CD19 CAR-T cells to ibrutinib would improve remission rates in CLL.
Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Researchers sought to determine the landscape of BTK inhibitors for treating patients with CLL.
Researchers sought to determine whether IgM levels would impact treatment responsiveness to ibrutinib in patients with CLL.
Combination acalabrutinib, obinutuzumab, and venetoclax did not meet the prespecified activity threshold in the CLL2-BAAG trial.
Researchers sought to determine whether there was a sustained benefit for patients with CLL receiving treatment with ibrutinib plus rituximab.
Researchers sought to determine whether there was a difference in PFS based on depth of response with ibrutinib at 1 year in patients with CLL.
Researchers sought to determine whether there was an association between ferroptosis-related genes and prognosis for patients with CLL.
Copiktra is an oral inhibitor of phosphoinositide 3-kinase.
Researchers sought to determine the case fatality rate in patients with CLL who were infected with SARS-CoV-2.
Researchers sought to determine whether there was a link between TAp63 and disease aggressiveness in patients with CLL.
Chronic lymphocytic leukemia (CLL) is a chronic incurable mature B-cell neoplasm that often does not require immediate treatment; however, when patients experience symptoms, such as anemia, cytopenias, or bulky lymphadenopathy, therapy is required. During a presentation at the 2022 Oncology Nurse Advisor Summit, Laura J. Zitella, MS, RN, ACNP-BC, AOCN, an associate clinical professor at…
Patients with CLL were significantly more likely to have an antibody response to the Moderna vaccine than to the Pfizer-BioNTech vaccine.
Researchers sought to determine whether adding venetoclax to R-EPOCH would induce durable responses in patients with Richter syndrome.
Researchers sought to determine whether adding obinutuzumab to ibrutinib for patients with CLL would permit earlier ibrutinib discontinuation.
Researchers are working towards developing CAR-T therapy to provide longer and more durable responses for patients with CLL.
Researchers sought to determine whether a third dose of the BNT162b2 mRNA vaccine against COVID-19 may induce an antibody response in patients with CLL or SLL.
A retrospective review of data from patients with CLL demonstrated varied adherence to guidelines for ramp up initiation and laboratory monitoring.
Researchers sought to determine whether age impacts survival in patients with CLL undergoing treatment with ibrutinib.
Novel prognostic index CLL-WONT identifies patients with chronic lymphocytic leukemia who are at low risk for ever requiring treatment
Researchers sought to determine whether MRD negativity could predict PFS in patients with CLL treated with ibrutinib.
Ibrutinib improved event-free survival, but its effect on overall survival is unclear.
There were no significant differences by treatment type.
Researchers sought to determine whether different doses of ponatinib would have benefit for patients with resistant chronic-phase chronic myeloid leukemia.
Researchers sought to determine whether MRD would improve after fixed-duration treatment with venetoclax and obinutuzumab therapy in patients with CLL.
Researchers sought to determine the impact of GST polymorphisms on the risk of B-ALL.
Researchers sought to determine whether patients with CLL whose disease develops resistance to both BTK and BCL2 inhibition have a poor prognosis.
Researchers sought to determine if F2-ISoP levels could be a biomarker for cognitive dysfunction in children with ALL.
Researchers sought to determine whether cell-in-cell interactions would have a role in drug resistance.
Researchers sought to determine whether acalabrutinib, venetoclax, and obinutuzumab would be a helpful option for frontline treatment of CLL.
Researchers sought to determine the efficacy of the COVID-19 vaccine in patients with CLL.
Researchers sought to determine whether activation of MAPK pathway genes may play a role in resistance to PI3K inhibitor therapy in patients with CLL.
An analysis of a registry of patients with CML and Philadelphia chromosome-positive ALL demonstrated that ponatinib is efficacious in those with relapsed or refractory disease.
A dose-reduction strategy in patients with CP-CML receiving dasatinib was shown to be feasible and may reduce adverse effects in these patients.
Researchers sought to clarify the current treatment strategies and challenges for patients with chronic lymphocytic leukemia.
At 4 years, there was no significant difference in overall survival.
Researchers sought to determine whether acalabrutinib would be safe and effective in patients with treatment-naïve CLL who declined or were in ineligible for chemotherapy.
Researchers sought to determine whether CAR T therapy would have a better result than pretransplant chemotherapy in patients with B-ALL undergoing allo-HSCT.
Researchers sought to determine whether umbralisib would be an effective treatment option for patients with CLL who cannot tolerate BTK or PI3Kδ inhibitors.
The tumor lysis syndrome risk decreased for 84.6% of patients in the ibrutinib/venetoclax group.
Activation of the MAPK/ERK pathway mediates resistance to PI3K inhibitors, researchers found.
The IDEAL trial found that adolescents and young adults with B-cell acute lymphoblastic leukemia may benefit from restrictive diets and increased exercise.
Researchers sought to determine the long-term safety and efficacy of KTE-X19 in pediatric and adolescent patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
A study was conducted to assess the safety and efficacy of fludarabine and cyclophosphamide combined with rituximab for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in elderly patients and those with comorbid conditions.
Researchers sought to determine factors that may impact infection risk in patients with CLL.
Investigators conducted a randomized controlled trial to determine whether the addition of ublituximab to treatment with ibrutinib improved outcomes in patients with relapsed or refractory chronic lymphocytic leukemia.